shanghai-biotech
(3)
Zhihua Xiao and the Art of Feeding the Invisible
A doctoral study of how blood cells cling together led to a career spent helping other cells thrive. At OPM Biosciences, Xiao has turned the quiet craft of culture media into a strategy for scale, supply and global reach.
Lishan Zhao Is Building Biotech for the Awkward Trip From Flask to Factory
After helping Amyris move engineered biology toward commercial products, the chemist founded Cataya around a stubborn lesson: a molecule matters only when the factory can make it reliably.
Joan Shen
Joan Huaqiong Shen is the founder and CEO of NeuShen Therapeutics, a clinical-stage biotech with R&D centers in Shanghai and Boston that develops treatments for psychiatric and neurological disorders. A physician-scientist trained in psychiatry and neurology, she spent decades leading central-nervous-system drug programs at Eli Lilly, Wyeth, Pfizer, Hengrui and Johnson & Johnson before running R&D and serving as CEO at I-Mab Biopharma, where she took the company public on Nasdaq and struck a global partnership with AbbVie. In 2026 NeuShen closed a Series A+ round led by Lilly Asia Ventures as its lead compound NS-136 advanced into Phase 2 trials.